Workflow
中美本维莫德乳膏对比：中国产品疗效与价格双优
Zhong Guo Jing Ji Wang·2025-05-20 09:10

Core Viewpoint - The approval of Benovolimod cream (Zelime) in China marks a significant advancement in the treatment of atopic dermatitis for patients aged 2 and above, being the first non-steroidal topical innovative drug globally for this indication, with a notable price and accessibility advantage over the US counterpart, VTAMA [1][4][9] Group 1: Development Background - Benovolimod was discovered in the 1990s by Dr. Chen Genghui during research in Canada, leading to the establishment of a patent shared between Canada and China [4] - Dr. Chen returned to China to establish Tianji Pharmaceutical, while the overseas development rights were acquired by GSK and later sold to Dermavant in the US [4] Group 2: Clinical Trials - Phase III clinical trial results show similar efficacy and safety profiles for both Zelime and VTAMA, with Zelime demonstrating superior efficacy in children aged 7-11 [6] - EASI75 response rates were 54.4% for Zelime and 55.8% for VTAMA, while IGA response rates were 46.2% for Zelime and 45.4% for VTAMA [6] Group 3: Price Comparison - The price of Zelime in China is 980 RMB per tube, while VTAMA costs approximately 1400 USD (around 9800 RMB), making VTAMA about ten times more expensive than Zelime [7] - Even when adjusted for weight, VTAMA remains 2.5 times more expensive than Zelime, significantly reducing the economic burden on Chinese patients [7] Group 4: Patient Feedback - Both Zelime and VTAMA received positive feedback from patients, with Chinese users highlighting its effectiveness in controlling itching and reducing flare-ups, especially for children [8] - American patients reported effective relief from eczema symptoms with VTAMA, despite its high price, as evidenced by sales reaching 20 million USD in the first quarter of 2025 [8] Group 5: Overall Summary - Overall, Zelime offers a more cost-effective and efficient treatment option for atopic dermatitis patients in China compared to VTAMA, benefiting from local development, superior pediatric efficacy, and broader patient acceptance [9]